Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Ali Mukherjee"'
Autor:
Ali Mukherjee, Youssouf Badal, Xuan-Thao Nguyen, Johanna Miller, Ahmed Chenna, Hasan Tahir, Alicia Newton, Gordon Parry, Stephen Williams
Publikováno v:
PLoS ONE, Vol 6, Iss 1, p e16443 (2011)
BackgroundThe identification of patients for targeted antineoplastic therapies requires accurate measurement of therapeutic targets and associated signaling complexes. HER3 signaling through heterodimerization is an important growth-promoting mechani
Externí odkaz:
https://doaj.org/article/3b1da752ec754496a6e2645d5a96cc18
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Figure 3 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::441f129dfef037b56d4ac8701219193c
https://doi.org/10.1158/0008-5472.22388685.v1
https://doi.org/10.1158/0008-5472.22388685.v1
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Figure 5 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::069c9a64faa82b3b5ad28af064325692
https://doi.org/10.1158/0008-5472.22388679
https://doi.org/10.1158/0008-5472.22388679
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Figure 2 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b7426b363aeac016f620c7feddf4960
https://doi.org/10.1158/0008-5472.22388688.v1
https://doi.org/10.1158/0008-5472.22388688.v1
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Figure Legends 1-5 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76fbf72fe0e25818c4e68211404ff25b
https://doi.org/10.1158/0008-5472.22388676.v1
https://doi.org/10.1158/0008-5472.22388676.v1
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Table 2 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8f2f754faec1d45da75b51d8e303313
https://doi.org/10.1158/0008-5472.22388667.v1
https://doi.org/10.1158/0008-5472.22388667.v1
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Figure 1 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c73dc389f0b8121d5e90fb8957f45d10
https://doi.org/10.1158/0008-5472.22388691
https://doi.org/10.1158/0008-5472.22388691
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Figure 4 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25aaa79574752c50947dc0f67a84cf7a
https://doi.org/10.1158/0008-5472.22388682.v1
https://doi.org/10.1158/0008-5472.22388682.v1
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Table 1 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ea34edadf397689779c57f8b480197f
https://doi.org/10.1158/0008-5472.22388670.v1
https://doi.org/10.1158/0008-5472.22388670.v1
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Methods from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91ac64b03b4de9aaa60ebd34ec268af9
https://doi.org/10.1158/0008-5472.22388673
https://doi.org/10.1158/0008-5472.22388673